FAZA PET/MRI in CLI Patients Pre and Post Revascularization

Last updated: March 25, 2025
Sponsor: University Health Network, Toronto
Overall Status: Active - Recruiting

Phase

N/A

Condition

Peripheral Arterial Occlusive Disease

Claudication

Occlusions

Treatment

FAZA PET/MRI scan

Clinical Study ID

NCT04054609
18-6114
  • Ages > 18
  • All Genders

Study Summary

Peripheral artery disease is a worldwide problem, leading to high mortality and mobility.

Critical limb ischemia (CLI) is associated with high risk of amputation with the subsequent decreased in life quality. Endovascular therapy is now considered the primary treatment option in these patients to improve the vascularity and prevent amputations.

In recent years, development of molecular imaging tools are now become available. A recent radio tracer named 18F-Fluoroazomycin Arabinoside (FAZA) its an specific marker of hypoxia in the tissues and has been used in multiples studies. This tracer can be used in PET/MR scan providing a potentially power diagnostic tool in patients with CLI, allowing in one diagnostic study the evaluation of location and degree of hypoxia in the extremity tissues. This diagnostic tool may offer a better assessment pre and post standard of care endovascular treatment for the patients.

Moreover, some of the patients treated with endovascular therapy may not have a favorable outcome, without a clear reason explaining this situation. We will try to find some predictor model in the FAZA PET/MR that can explain the different outcomes and may help clinicians choose the best treatment option in specific cases.

Thirdly, post processing for optimization of the MR sequences in patients with CLI will be performed at the MR component of the PET. There would thus be great clinical interest in developing non-invasive tools that could provide more accurate diagnostic information compared to traditional tests for these patients population.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age >= 18 years;

  • Patients with clinical evidence of critical limb ischemia that are candidates forrevascularization treatment;

  • A negative urine or serum pregnancy test in women of child-bearing age;

  • Ability to provide written informed consent to participate in the study.

Exclusion

Exclusion Criteria:

  • Contraindication for MR as per current institutional guidelines;

  • Inability to lie supine for at least 30 minutes;

  • Pregnant or breastfeeding;

  • Unable or unwilling to provide informed consent;

  • Impending amputation within 6 weeks of presentation;

  • Previous metallic hardware in the lower limbs;

  • Unable to have ethanol.

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: FAZA PET/MRI scan
Phase:
Study Start date:
August 31, 2019
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • University Health Network

    Toronto, Ontario M5G 2N2
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.